Table 1 Characteristics of CRIC study participants stratified by history of HF hospitalization after year 4.
Characteristics | Overall (N = 2673) | HF hospitalization (N = 472) | No HF hospitalization (N = 2201) | P value |
|---|---|---|---|---|
Demographics | ||||
Mean (SD) age at baseline, years | 61.7 (10.6) | 64.6 (9.1) | 61.1 (10.8) | < 0.001 |
Women, n (%) | 1217 (45.5) | 204 (43.2) | 1013 (46.0) | 0.27 |
Race/ethnicity, n (%) | < 0.001 | |||
Non-Hispanic White | 1187 (44.4) | 168 (35.6) | 1019 (46.3) | |
Non-Hispanic Black | 1078 (40.3) | 239 (50.6) | 839 (38.1) | |
Hispanic | 305 (11.4) | 47 (10.0) | 258 (11.7) | |
Other | 103 (3.9) | 18 (3.8) | 85 (3.9) | |
Current smoker, n (%) | 251 (9.4) | 58 (12.3) | 193 (8.8) | < 0.05 |
Medical history, n (%) | ||||
Heart failure | 332 (12.4) | 153 (32.4) | 179 (8.1) | < 0.001 |
Prior heart failure hospitalization | 219 (8.2) | 108 (22.9) | 111 (5.0) | < 0.001 |
Atrial fibrillation or other arrhythmia | 560 (21.0) | 171 (36.2) | 389 (17.7) | < 0.001 |
Coronary heart disease | 743 (27.8) | 239 (50.6) | 504 (22.9) | < 0.001 |
Peripheral vascular disease | 219 (8.2) | 62 (13.1) | 157 (7.1) | < 0.001 |
Stroke | 321 (12.0) | 87 (18.4) | 234 (10.6) | < 0.001 |
Hypertension | 2468 (92.3) | 466 (98.7) | 2002 (91.0) | < 0.001 |
Diabetes mellitus | 1369 (51.2) | 330 (69.9) | 1039 (47.2) | < 0.001 |
Vital signs, mean (SD) | ||||
Body mass index, kg/m2 | 31.9 (7.8) | 33.7 (8.7) | 31.6 (7.5) | < 0.001 |
Body surface area, m2 | 2.0 (0.3) | 2.1 (0.3) | 2.0 (0.3) | < 0.001 |
Systolic blood pressure, mmHg | 127.3 (21.3) | 132.4 (23.7) | 126.3 (20.7) | < 0.001 |
Diastolic blood pressure, mmHg | 69.0 (12.3) | 67.5 (12.8) | 69.3 (12.2) | < 0.01 |
Laboratory values, mean (SD) | ||||
Estimated glomerular filtration rate, mL/min/1.73m2 | 41.7 (18.1) | 34.0 (14.8) | 43.3 (18.3) | < 0.001 |
Urine protein-to-creatinine ratio, g/g | 0.9 (2.0) | 1.3 (2.1) | 0.8 (2.0) | < 0.001 |
High-density lipoprotein, mg/dL | 47.0 (15.5) | 44.5 (14.7) | 47.6 (15.6) | < 0.01 |
Low-density lipoprotein, mg/dL | 98.5 (33.5) | 91.1 (33.1) | 100.1 (33.4) | < 0.001 |
Hemoglobin, g/dL | 12.6 (1.7) | 12.0 (1.7) | 12.8 (1.7) | < 0.001 |
Glycosylated hemoglobin, % | 6.5 (1.4) | 6.7 (1.4) | 6.5 (1.4) | < 0.05 |
Brain natriuretic peptide, pg/mL (YEAR 1) | 75.9 (163.7) | 139.3 (279.3) | 62.3 (121.5) | < 0.001 |
Medications | ||||
ACE inhibitors | 1139 (42.6) | 195 (41.3) | 944 (42.9) | 0.52 |
Angiotensin receptor blockers | 753 (28.2) | 142 (30.1) | 611 (27.8) | 0.31 |
Alpha blockers | 537 (20.1) | 144 (30.5) | 393 (17.9) | < 0.001 |
Beta blockers | 1435 (53.7) | 346 (73.3) | 1089 (49.5) | < 0.001 |
Calcium channel blockers | 1132 (42.4) | 239 (50.6) | 893 (40.6) | < 0.001 |
Digoxin | 69 (2.6) | 27 (5.7) | 42 (1.9) | < 0.001 |
Loop diuretics | 951 (35.6) | 286 (60.6) | 665 (30.2) | < 0.001 |
Thiazide diuretics | 559 (20.9) | 79 (16.7) | 480 (21.8) | < 0.05 |
Potassium sparing diuretics | 187 (7.0) | 51 (10.8) | 136 (6.2) | < 0.001 |
Statins | 1693 (63.4) | 344 (72.9) | 1349 (61.3) | < 0.001 |
NSAIDs | 1504 (56.3) | 303 (64.2) | 1201 (54.6) | < 0.001 |
Aspirin | 1333 (49.9) | 281 (59.5) | 1052 (47.8) | < 0.001 |
